Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P200014/S012

cobas EZH2 Mutation Test

Roche Molecular System, Inc. · Decision date Oct 27, 2026

MEDTECHLEDGER EXPLANATIONP200014/S012

What did the FDA decide?

The FDA recorded decision OK30 on 2026-10-27 for supplement P200014/S012, filed by Roche Molecular System, Inc. under a 30-Day Notice. The supplement concerns the cobas® EZH2 Mutation Test, a somatic gene mutation detection system classified under product code OWD in the Pathology specialty. The recorded statement describes a change to the manufacturing process for oligonucleotides.

This action covers a manufacturing process change rather than a new approval of the whole test system. The source record does not identify which oligonucleotides are affected, the nature of the process change, or any supporting documentation, so the technical scope and any effect on device performance remain unknown. Whether the notice was acknowledged without further FDA action is not stated beyond the OK30 decision code.

FDA approval order statement

to change the manufacturing process for oligonucleotides
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Pathology
Decision date
Oct 27, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P200014/S012
Regulatory pathway
PMA supplement
Product code
OWD
Decision code
OK30
Decision date
Oct 27, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Somatic gene mutation detection system.

Product code
OWD
FDA device class
3

For the original device and its historical approval scope, see PMA P200014. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P200014 · Original PMA

    cobas EZH2 Mutation Test

  2. P200014/S012 received

    Application receipt date recorded by FDA.

  3. P200014/S012 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P200014. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200014

Product / regulatory recordCompanyPathwayDecision dateSource
Roche Molecular System, Inc.PMA decisionJun 18, 2020FDA

Explore the linked device profile

Other records with product code OWD

Product / regulatory recordCompanyPathwayDecision dateSource
Roche Molecular Systems, Inc.PMA supplementNov 4, 2026FDA
RochePMA supplementNov 4, 2026FDA
Roche Molecular Systems, Inc.PMA supplementNov 4, 2026FDA
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
RochePMA supplementOct 27, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Roche Molecular System, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
4300 Hacienda Dr., Pleasanton, CA, 94588

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records